The pharmacokinetics, pharmacodynamics and clinical efficacy of elvitegravir plus cobicistat plus emtricitabine plus tenofovir combination therapy for the treatment of HIV

被引：7

作者：

Raffe, Sonia ^{[1
]}

Fisher, Martin ^{[1
]}

机构：

[1] Royal Sussex Cty Hosp, Brighton BN2 5BE, E Sussex, England

来源：

EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY | 2015年 / 11卷 / 03期

关键词：

cobicistat; elvitegravir; HIV; Stribild; NON-INFERIORITY TRIAL; REGIMEN ELVITEGRAVIR/COBICISTAT/EMTRICITABINE/TENOFOVIR DF; CO-FORMULATED ELVITEGRAVIR; INITIAL TREATMENT; DOUBLE-BLIND; INFECTION ANALYSIS; COFORMULATED ELVITEGRAVIR; DISOPROXIL FUMARATE; OPEN-LABEL; IN-VITRO;

D O I：

10.1517/17425255.2015.997207

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Introduction: Co-formulated elvitegravir, cobicistat, emtricitabine and tenofovir (EVG/COBI/FTC/TDF or Stribild (TM)) is the latest antiretroviral tablet approved in the EU. This review aims to provide an overview of its role in the management of HIV-1 infection. Areas covered: This review covers material searched and obtained through Medline and Pubmed up to July 2014. Expert opinion: Antiretroviral treatment prevents the progressive destruction of the immune system by the HIV, significantly reducing morbidity and mortality. The efficacy and tolerability of EVG/COBI/FTC/TDF compared to current standard of care as a single-tablet treatment choice has been shown in study 102 and study 103. Its use is restricted to patients without significant pre-existing renal impairment and may be limited by concomitant medications but undoubtedly increases treatment choice for HIV-1-infected adults.

引用

页码：427 / 435

页数：9

共 24 条

[11]

Gilead Sciences International Ltd, 2013, SUMM PROD CHAR TRUV, P1

[12]

Gilead Sciences International Ltd, 2012, SUMM PROD CHAR EMTR, P1

[13] Antiretroviral Treatment of Adult HIV Infection 2014 Recommendations of the International Antiviral Society-USA Panel [J].

Guenthard, Huldrych F. ;

Aberg, Judith A. ;

Eron, Joseph J. ;

Hoy, Jennifer F. ;

Telenti, Amalio ;

Benson, Constance A. ;

Burger, David M. ;

Cahn, Pedro ;

Gallant, Joel E. ;

Glesby, Marshall J. ;

Reiss, Peter ;

Saag, Michael S. ;

Thomas, David L. ;

Jacobsen, Donna M. ;

Volberding, Paul A. .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2014, 312 (04) :410-425

[14] Cobicistat Boosts the Intestinal Absorption of Transport Substrates, Including HIV Protease Inhibitors and GS-7340, In Vitro [J].

Lepist, Eve-Irene ;

Phan, Truc K. ;

Roy, Anupma ;

Tong, Leah ;

MacLennan, Kelly ;

Murray, Bernard ;

Ray, Adrian S. .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2012, 56 (10) :5409-5413

[15]

Panel on Antiretroviral Guidelines for Adults and Adolescents, 2014, GUID US ANT AG HIV 1, P1

[16]

Post F, 2013, TUPE280 7 IAS C KUAL, P1

[17] Switching to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of non-nucleoside reverse transcriptase inhibitor with emtricitabine and tenofovir in virologically suppressed adults with HIV (STRATEGY-NNRTI): 48 week results of a randomised, open-label, phase 3b non-inferiority trial [J].

Pozniak, Anton ;

Markowitz, Martin ;

Mills, Anthony ;

Stellbrink, Hans-Juergen ;

Antela, Antonio ;

Domingo, Pere ;

Girard, Pierre-Marie ;

Henry, Keith ;

Thai Nguyen ;

Piontkowsky, David ;

Garner, Will ;

White, Kirsten ;

Guyer, Bill .

LANCET INFECTIOUS DISEASES, 2014, 14 (07) :590-599

[18] A Randomized, Double-Blind Comparison of Coformulated Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF vs Ritonavir-Boosted Atazanavir Plus Coformulated Emtricitabine and Tenofovir DF for Initial Treatment of HIV-1 Infection: Analysis of Week 96 Results [J].

Rockstroh, Juergen K. ;

DeJesus, Edwin ;

Henry, Keith ;

Molina, Jean-Michel ;

Gathe, Joseph ;

Ramanathan, Srinivasan ;

Wei, Xuelian ;

Plummer, Andrew ;

Abram, Michael ;

Cheng, Andrew K. ;

Fordyce, Marshall W. ;

Szwarcberg, Javier .

JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2013, 62 (05) :483-486

[19] Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks [J].

Sax, Paul E. ;

DeJesus, Edwin ;

Mills, Anthony ;

Zolopa, Andrew ;

Cohen, Calvin ;

Wohl, David ;

Gallant, Joel E. ;

Liu, Hui C. ;

Zhong, Lijie ;

Yale, Kitty ;

White, Kirsten ;

Kearney, Brian P. ;

Szwarcberg, Javier ;

Quirk, Erin ;

Cheng, Andrew K. .

LANCET, 2012, 379 (9835) :2439-2448

[20] Evaluation of the Effect of Cobicistat on the In Vitro Renal Transport and Cytotoxicity Potential of Tenofovir [J].

Stray, Kirsten M. ;

Bam, Rujuta A. ;

Birkus, Gabriel ;

Hao, Jia ;

Lepist, Eve-Irene ;

Yant, Stephen R. ;

Ray, Adrian S. ;

Cihlar, Tomas .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2013, 57 (10) :4982-4989

← 1 2 3 →